Addendum: LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin&#x2019;s lymphoma models and in cells deficient in DNA damage repair

Jianli Zhou; Drew Sturtevant; Cassie Love; Aditya Kulkarni; Neha Biyani; Umesh Kathad; Elizabeth Thacker; Sandeep Dave; Kishor Bhatia

doi:10.18632/oncotarget.28479

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Addendum:

Addendum: LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin’s lymphoma models and in cells deficient in DNA damage repair

PDF | How to cite

Oncotarget. 2023; 14:722-722. https://doi.org/10.18632/oncotarget.28479

Metrics: PDF 590 views | ?

Jianli Zhou¹, Drew Sturtevant¹, Cassie Love², Aditya Kulkarni¹, Neha Biyani¹, Umesh Kathad¹, Elizabeth Thacker³, Sandeep Dave² and Kishor Bhatia¹

¹Lantern Pharma Inc., Plano, TX 75024, USA
²Department of Medicine, Duke University, Durham, NC 27708, USA
³Data Driven Bioscience, Durham, NC 27707, USA

Published: July 20, 2023

Copyright: © 2023 Zhou et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has an addendum: Wet-lab experiments conducted at Data Driven Bioscience, Rincon Biosciences, Reprocell Inc., intoDNA, and Toxys Europe were funded by Lantern Pharma Inc.

Original article: Oncotarget. 2023; 14:597-611. DOI: https://doi.org/10.18632/oncotarget.28454.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28479

Publication Alerts

Post-Publication Promotion

Publication Discount

Addendum:

Addendum: LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin’s lymphoma models and in cells deficient in DNA damage repair